Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy

Health Technology Assessment

Volumn 7, Issue 31, 2003, Pages

  Law, M ^a   Wald, N ^a   Morris, J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; CHLOROTHIAZIDE; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LABETALOL; METOLAZONE; PINDOLOL; PLACEBO; PROPRANOLOL; QUINAPRIL; RAMIPRIL; RESERPINE; SPIRAPRIL; THIAZIDE DIURETIC AGENT; TIMOLOL; TRANDOLAPRIL; UNINDEXED DRUG;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; AGE; ANAMNESIS; ANGIONEUROTIC EDEMA; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ATHEROGENESIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; COLD LIMB; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FLUSHING; GOUT; HEADACHE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; IMPOTENCE; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METABOLIC DISORDER; MORTALITY; MUSCLE CRAMP; NAUSEA; PRACTICE GUIDELINE; PREDICTION; PREVENTIVE MEDICINE; RAYNAUD PHENOMENON; RECURRENT DISEASE; REVIEW; SCREENING; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIVID DREAM; CEREBROVASCULAR ACCIDENT; INCIDENCE; PATHOPHYSIOLOGY; RISK FACTOR; UNITED KINGDOM;

ANTIHYPERTENSIVE AGENTS; ENGLAND; HUMANS; HYPERTENSION; INCIDENCE; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STROKE; WALES;

EID: 0037824108     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta7310     Document Type: Review

References (531)

1. Prescott-Clarke P, Primatesta P. Health Survey for England, 1996. Norwich: The Stationery Office; 1998.
2. Armitage P, Fox W, Rose GA, Tinker CM. The variability of measurements of casual blood pressure. II: Survey experience. Clin Sci 1966;30:337-44.
3. Office for National Statistics. Mortality Statistics; Cause: England and Wales. Norwich: The Stationery Office; 1999.
4. Malmgren R, Warlow C, Bamford J, Sandercock P. Geographical and secural trends in stroke incidence. Lancet 1987;ii:1196-200.
5. Sudlow CLM, Warlow CP, for the International Stroke Incidence Collaboration. Comparable studies of the incidence of stroke and its pathological types. Stroke 1997;28:491-9.
6. Stewart JA, Dundas R, Howard RS, Rudd AG, Wolfe CDA. Ethnic differences in incidence of stroke: Prospective study with stroke register. BMJ 1999;318:967-71.
7. Du X, Sourbutts J, Cruickshank K, Summers A, Roberts N, Walton E, et al. A community based stroke register in a high risk area for stroke in north west England. J Epidemiol Community Health 1997;51:472-8.
8. Wolfe CDA, Taub NA, Bryan S, Beech R, Warburton F, Burney PGJ. Variations in the incidence, management and outcome of stroke in residents under the age of 75 in two health districts of southern England. J Public Health Med 1995;17:411-18.
9. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K, et al. A prospective study of acute cerebrovascular disease in a community: The Oxfordshire Community Stroke Project 1981-86. J Neurol Neurosurg Psychiatry 1988;51:1373-80.
10. Lauria G, Gentile M, Fassetta G, Casetta I, Agnoli F, Andreotta G, et al. Incidence and prognosis of stroke in the Belluno Province, Italy. Stroke 1995;26:1787-93.
11. D'Alessandro G, Di Giovanni M, Roveyaz L, Iannizzi L, Compagnoni MP, Blanc S, et al. Incidence and prognosis of stroke in the Valle d'Aosta, Italy. Stroke 1992;23:1712-15.
12. Ricci S, Celani MG, La Rosa F, Vitali R, Duca E, Ferraguzzi R, et al. SEPIVAC: A community-based study of stroke incidence in Umbria, Italy. J Neurol Neurosurg Psychiatry 1991;54:695-8.
13. Giroud M, Milan C, Beuriat P, Gras P, Essayagh E, Arveux P, et al. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks. The Stroke Registry of Dijon: 1985-9. Int J Epidemiol 1991;20:892-9.
14. Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, et al. Stroke incidence and case fatality in Southern Greece. Stroke 1998;30:363-70.
15. Truelsen T, Prescott E, Grønbaek M, Schnohr P, Boysen G. Trends in stroke incidence. The Copenhagen City Heart Study. Stroke 1997;28:1903-7.
16. Jøgensen HS, Plesner A, Hübbe P, Larsen K. Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg, Denmark. Stroke 1992;23:1701-4.
17. Ellakjær H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in Innherred, Norway, 1994-1996. Stroke 1997;28:2180-4.
18. Jerntorp P, Berglund G. Stroke registry in Malmö, Sweden. Stroke 1992;23:357-61.
19. Åsberg KH, Parrow A. Event, incidence, and fatality rates of cerebrovascular diseases in Enköping-Håbo, Sweden, 1986-1988. Scand J Soc Med 1991;19:134-9.
20. Fogelholm R, Murros K, Rissanen A, Ilmavirta M. Decreasing incidence of stroke in central Finland, 1985-1993. Acta Neurol Scand 1997;95:38-43.
21. Numminen H, Kotila M, Waltimo O, Aho K, Kaste M. Declining incidence and mortality rates of stroke in Finland from 1972-1991. Stroke 1996;27:1487-91.
22. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival. Secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-80.
23. Bonita R, Broad JB, Beaglehole R. Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91. Lancet 1993;342:1470-3.
24. Anderson CS, Jamrozik KD, Burvill PW, Chakera TMH, Johnson G, Stewart-Wynne EG. Ascertaining the true incidence of stroke: Experience from the Perth Community Stroke Study, 1989-1990. Med J Aust 1993;158:80-4.
25. Norris RM. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. BMJ 1998;316:1065-70.
26. Volmink JA, Neton JN, Hicks NR, Sleight P, Fowler GH, Neil HAW. Coronary event and case fatality rates in an English population: Results of the Oxford myocardial infarction incidence study. Heart 1998;80:40-4.
27. Kirchhoff M, Davidsen M, Brønnum-Hansen H, Hansen B, Schnack H, Eriksen LS, et al. Incidence of myocardial infarction in the Danish MONICA population 1982-1991. Int J Epidemiol 1999;28:211-18.
28. Wilhelmsen L, Rosengren A, Johansson S, Lappas G. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Göteborg, Sweden. Eur Heart J 1997;18:572-81.
29. Tydén P, Hansen O, Janzon L. Intra-urban variations in incidence and mortality in myocardial infarction. Eur Heart J 1998;19:1795-801.
30. Tuomilehto J, Arstila M, Kaarsalo E, Kankaanpää J, Ketonen M, Kuulasmaa K, et al. Acute myocardial infarction (AMI) in Finland - Baseline data from the FINMONICA AMI register in 1983-1985. Eur Heart J 1992;13:577-87.
31. Law MR, Wald NJ. Risk factor thresholds: Their existence under scrutiny. BMJ 2002;324:1570-6.
32. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
33. Van Den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menott A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
34. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
35. MacMahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000;342:50-1.
36. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
37. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707-16.
38. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
39. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998;352:1801-7.
40. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64.
41. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997;277:739-45.
42. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: I. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 1967;202:1028-34.
43. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970;213:1143-52.
44. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71.
45. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982;247:633-8.
46. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in 'mild' hypertension. N Engl J Med 1982;307:976-80.
47. Hypertension Detection and Follow-up Program Cooperative Group. Effect of stepped care on the incidence of myocardial infarction and angina pectoris. Hypertension 1984;6 (Suppl 1):198-206.
48. US Public Health Service Hospitals Cooperative Study Group (Smith WM). Treatment of mild hypertension: Results of a ten-year intervention trials. Circ Res 1977;40 (Suppl 1):98-105.
49. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo Study. Am J Med 1980;69:725-32.
50. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension. Lancet 1991;338:1281-5.
51. Australian National Blood Pressure Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980;i:1261-7.
52. Amery A, Birkenberger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;i:1349-54.
53. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. BMJ 1985;291:97-104.
54. Hansson L for the BBB Study Group. The BBB study: The effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in 'well-treated' hypertensive patients. Blood Pressure 1994;3:248-54.
55. Coope J, Warrneder TS. Randomised trial of treatment of hypertension in the elderly in primary care. BMJ 1986;293:1145-51.
56. Veterans Administrative/National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Ann NY Acad Sci 1978;304:267-88.
57. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992;304:405-12.
58. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
59. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974;229:409-18.
60. Carter AB. Hypotensive therapy in stroke survivors. Lancet 1970;i:485-9.
61. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
62. Hansson L, Zanchetti A, Carruthers SG, Hahlöf B, Elmfeldt D, Junis S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
63. Perry HM, Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD, et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke 1989;20:4-13.
64. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-64.
65. Gueyffier F, Boissel J-P, Boutitie F, Pocock S, Coope J, Cutler J, et al. The INDANA Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke. Stroke 1997;28:2557-62.
66. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
67. PATS Collaborating Group. Post-stroke antihypertensive treatment study. Chin Med J 1995;108:710-17.
68. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: Systemic review and meta regression analysis. BMJ 1999;318:1730-7.
69. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-5.
70. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
71. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
72. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
73. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
74. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
75. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-1.
76. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al. Use of ramipril in preventing stroke: Double blind randomised trial. BMJ 2000;324:699-702.
77. Svensson P, De Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures. Hypertension 2001;38:e28-e32.
78. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000;36:438-43.
79. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. Circulation 2000;102:1748-54.
80. Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-28.
81. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
82. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-85.
83. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected myocardial infarction. Arch Intern Med 1993;153:345-53.
84. Rengo F, Carbonin P, Pahor M, De Caprio L, Bernabei R, Ferrara N et al. A controlled trial of verapamil in patients after acute myocardial infarction: Results of the Calcium Antagonist Reinfarction Italian study (CRIS). Am J Cardiol 1996;77:365-9.
85. DEFIANT-II Research Group. Doppler flow and echocardiography in functional cardiac insufficiency: Assessment of nisoldipine therapy. Eur Heart J 1997;18:31-40.
86. Boden WE, Van Gilst WH, Scheidwaert RG, Starkey IR, Carlier MF, Julian DG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomised placebo-controlled trial. Lancet 2000;355:1751-6.
87. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini J, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10.
88. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
89. Garg R, Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
90. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holsgrove H, Hosie J. Beta-blockers versus diuretics in hypertensive men: Main results from the HPPHY trial. J Hypertens 1987;5:561-72.
91. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension: Mortality results from the MAPHY study. JAMA 1988;259:1976-82.
92. IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker exprenolol: The international prospective primary prevention study in hypertension (IPPSH). J Hypertens 1985;3:379-92.
93. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality in ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-22.
94. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial function. Lancet 1995;345:669-85.
95. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73.
96. Tuomilehto J, Ryynänen O-P, Koistinen A, Rastenyte D, Nissinen A, Puska P. Low diatolic blood pressure and mortality in a population-based cohort of 16 913 hypertensive patients in North Karelia, Findland. J Hypertens 1998;16:1235-42.
97. Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: Report of the European Working Party on High Blood Pressure in the Elderly. BMJ 1989;298:1552-6.
98. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet 1978:ii:1139-41.
99. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;i:581-3.
100. D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: The Framingham study. BMJ 1991;303:385-9.
101. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: Is there a point beyond which blood pressure reduction is dangerous? JAMA 1991;265Z;489-95.
102. Witteman JCM, Grobbee DE, Valkenburg HA, Van Hemert AM, Stijnen T, Burger H, et al. J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet 1994;343:504-7.
103. Bots ML, Witteman JCM, Hofman A, De Jong PTVM, Grobbee DE. Low diatolic blood pressure and atherosclerosis in elderly subjects. Arch Intern Med 1996;156:843-8.
104. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, et al. Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 1994;343:75-9.
105. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med 1993;153:598-615.
106. Rose G. Strategy of prevention: Lessons from cardiovascular disease. BMJ 1981;282:1947-51.
107. Rose G. The Strategy of Prevention Medicine. Oxford: Oxford University Press, 1992.
108. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-5.
109. Guidelines Sub-Committee. 1989 Guidelines for the management of mild hypertension: Memorandum from a WHO/ISH meeting. J Hypertens 1989;7:689-93.
110. Beevers G, Lip GYH, O'Brien E. ABC of Hypertension. London: BMJ Books, 1987.
111. Jackson R, Barham P, Maling T, MacMahon S, Bills J, Birch T, et al. The management of raised blood pressure in New Zealand. BMJ 1993;307:107-10.
112. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [published erratum appears in Arch Intern Med 1998;158:573]. Arch Intern Med 1997;157:2413-46.
113. Guidelines Sub-Committee. 1999 World Health Organization - International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
114. Ramsey LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.
115. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston JF, et al. British Hypertension Society guidelines for hypertension management 1999: Summary. BMJ 1999;319:630-5.
116. Simpson FO, Gilchrist AR. Prognosis in untreated hypertensive vascular disease. Scott Med J 1958;1:1-14.
117. Sokolow M, Perloff D. The prognosis of essential hypertension treated conservatively. Circulation 1961;23:697-713.
118. Griep AH, Barry GR, Hall WC, Hoobler SW. The prognosis in arterial hypertension: Report in 117 patients under 53 years of age followed 8 to 10 years. Am J Med Sci 1951;221:239-49.
119. Hamilton M, Thompson EN, Wisniewski TKM. The role of blood-pressure control in preventing complications of hypertension. Lancet 1964;i:235-8.
120. Wolff FW, Lindeman RD. Effects of treatment in hypertension. J Chronic Dis 1966;19:227-40.
121. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000;320:659-61.
122. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction chart. BMJ 2000;320:709-10.
123. Ramsey LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table. Lancet 1996;348:387-8.
124. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140:199-270.
125. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel J-P. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001;323:75-81.
126. Padwal R, Straus, SE, McAlister FA. Cardiovascular risk factors and their effects on the decision to treat hypertension: Evidence based review. BMJ 2001;322:977-80.
127. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2003;162:2405-10.
128. Marquarsden J. The natural history of acute cerebrosvascular disease. Acta Neurol Scand 1969; 45 (Suppl 38):90-159.
129. Sacco R L, Wolf P A, Kannel W B, McNamara PM. Survival and recurrence following stroke: The Framingham study. Stroke 1982;13:290-5.
130. Ebrahim S. Clinical Epidemiology of Stroke. Oxford: Oxford University Press, 1990.
131. Warlow CP. Cerebrovascular disease. In Weatherall DJ, Ledingham JGG, Warrel DA, editors. Oxford Textbook of Medicine. 3rd ed. Oxford: Oxford University Press, 1996: pp. 3946-65.
132. Joint Health Surveys Unit, National Centre for Social Research, Department of Epidemiology and Public Health at the Royal Free and University College Medical School. Health Survey for England, 1998. Norwich: The Stationery Office; 1999.
133. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice. BMJ 1998;316:1430-4.
134. Ellerbeck EF, Jencks SF, Radford MJ, Kersowik TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA 1995;273:1509-14.
135. Avanzini F, Zuanetti G, Latini R, Colombo F, Santoro E, Maggioni AP, et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: A case for evidence-based medicine? Eur Heart J 1997;18:1447-56.
136. Imperical Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: Results of the OXCHECK study after one year. BMJ 1994;308:308-12.
137. Meissner I, Whisnant J, Garraway WM. Hypertension and stroke recurrence in a community (Rochester, Minnesota). Stroke 1988;19:459-63.
138. Merrett JD, Adams GF. Comparison of mortality rates in elderly hypertensive and normotensive hemiplegic patients. BMJ 1966;2:802-5.
139. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. Atrial fibrillation and stroke: Prevalence in different types of stroke and influence on early and long term prognosis. BMJ 1992;305:1460-5.
140. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
141. Seedat YK. Varying responses to hypotensive agents in different racial groups: Black versus white differences. J Hypertens 1989;7:515-18.
142. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulatory: September 2001. London: BMJ Books, 2001.
143. Reynolds JEF, editor. Martindale: The Extra Pharmacopoeia. London: Royal Pharmaceutical Society, 1996.
144. Monthly Index of Medical Specialties (MIMS). London: Haymarket Medical, August 2001.
145. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: Methodological issues. Int J Epidemiol 2002;31:140-9.
146. Hansson L, Smith DHG, Reeves R, Lapuerta P. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 2000;160:1654-8.
147. Stewart KJ, Effron MB, Valenti SA, Kelemen MH. Effects of diltiazem or propranolol during exercise training of hypertensive men. Med Sci Sports Exercise 1990;22:171-7.
148. Morice AH, Lowry R, Brown MJ, Higenbottam T. Angiotensin-converting enzyme and the cough reflex. Lancet 1987;ii:116-18.
149. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. BMJ 1987;294:1521-3.
150. Israili ZH, Dallas Hall Z. Cough and angioneurotic edema associates with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992;117:234-42.
151. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WHW, et al. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition. JAMA 1988;260:967-70.
152. Paster RZ, Snavely DB, Sweet AR, Draper RA, Goldberg AI, Soffer BA, et al. Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin Ther 1998;20:978-89.
153. Lacourcière Y. The incidence of cough: A comparison of lisinopril, placebo and temisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999;53:99-103.
154. Tanser PH, Campbell LM, Carranza J, Karrash J, Toutouzas P, Watts R. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Am J Hypertens 2000;13:214-18.
155. Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: A randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001;15:863-7.
156. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.
157. Benz J, Oshrain C, Henry D, Avery C, Chiang Y-T, Gatlin M. Valsartan, a new angiotensin II receptor antagonist: A double blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide J Clin Pharmacol 1997;37:101-7.
158. Chan P, Tomlinson B, Huang T-Y, Ko J-T, Lin T-S, Lee Y-S. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997;37:253-7.
159. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995;333:1572.
160. Grimm RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Hypertension 1997;29:8-14.
161. Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1981;ii:539-43.
162. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996;101 (Suppl 3A):71A-82A.
163. Ames RP. Antihypertensive drugs and lipid profiles. Am J Hypertens 1988;1:421-7.
164. Freis ED, Materson BJ. Short-term versus long-term in serum cholesterol with thiazide diuretics along. Lancet 1984;i:1414-15.
165. Freis ED. Critique of the clinical importance of diurectic-induced hypokalemia and elevated cholesterol level. Arch Intern Med 1989;149:2640-8.
166. Greenberg G, Brennan PJ, Miall WE. Effects of diuretic and beta-blocker therapy in the Medical Research Council Trail. Am J Med 1984;76(2A):45-51.
167. Amery A, Birkenhager W, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, et al. Influence of anti-hypertensive therapy on serum cholesterol in elderly hypertensive patients. Results of trial by the European Working Party on High Blood Pressure in the Elderly. Acta Cardiol 1982;37:235-44.
168. Helgeland A, Hjermann I, Leren P. High-density lipoprotein cholesterol and antihypertensive drugs. The Oslo study. BMJ 1978;2:403.
169. Grimm RH, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996;275:1549-55.
170. Papademetriou V, Price M, Johnson E, Smith M, Freis ED. Early changes in plasma and urinary potassium in diuretic-treated patients with systematic hypertension. Am J Cardiol 1984;54:1015-19.
171. Wilkinson PR, Issler H, Hesp R, Raftery EB. Total body and serum potassium during prolonged thiazide therapy for essential hypertension. Lancet 1975;i:759-62.
172. Papademetriou V, Burris JF, Notargiacomo A, Fletcher RD, Freis ED. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med 1988;148:1272-6.
173. Kaplan NM, Carnegie A, Raskin P, Heller JA, Simmons M. Potassium supplementation in hypertensive patients with diuretic-induced hypokelemia. N Engl J Med 1985;312:746-9.
174. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follman D, et al. Effects of oral potassium on blood pressure. JAMA 1997;277:1624-32.
175. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421-6.
176. Langford HG, Blaufox MD, Borhani NO, Curb D, Molteni A, Schneider KA, et al. Is thiazide-produced uric acid elevation harmful? Arch Intern Med 1987;147:645-9.
177. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; A fourteen-year follow-up. Lancet 1982;ii:1293-5.
178. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12.
179. Wasnich R, Davis J, Ross P, Vogel J. Effect of thiazide on rates of bone mineral loss: A longitudinal study. BMJ 1990;301:1303-5.
180. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990;322:286-90.
181. Ray WA, Griffin MR, Downney W, Melton LJ. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989;i:687-90.
182. Navis G, Faber HJ, De Zeeuw D, De Jong PE. ACE inhibitors and the kidney. Drug Saf 1996;15:200-11.
183. Kalra PA, Mamtora H, Holmes AM, Waldek S. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med 1990;282:1013-18.
184. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-11.
185. Wright JT, Bakris F, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002;288:2421-31.
186. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
187. Jarrett RJ, Shipley MJ, Rose G. Weight and mortality in the Whitehall Study. BMJ 1982;285:535-7.
188. Law MR, Thompson SG, Wald NJ. Assessing possible hazards for reducing serum cholesterol. BMJ 1994;308:373-9.
189. Frei M, Küster L, Von Krosigk PG, Koch H, Küppers. Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994;24 (Suppl 1):S25-S28.
190. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990; 263: 1507-12.
191. Petersen JR, Drabaek H, Gleerup G, Mehlsen J, Petersen LJ, Winther K. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapil in mild to moderate hypertension. Angiology 1996;47:233-40.
192. Scholze J, Breitstadt A, Cairns V, Bauer B, Bender N, Priestley, et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: A clinical trial of factorial design. J Hypertens 1993;11:217-21.
193. Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990;39:327-32.
194. Muiesan G, Agabiti-Rosei E, Buoninconti R, Cagli V, Carotti A, Corea L, et al. Antihypertensive efficacy and tolerability of captopril in the elderly: Comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study. J Hypertens 1987;5 (Suppl 5):S599-S602.
195. Kayanakis JG, Baulac L. Comparative study of once-daily administration of captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension. Br J Clin Pharmacol 1987;23 (Suppl 1):89S-92S.
196. Wing LMH, Arnold LF, Harvey PJ, Upton J, Molloy D, Bune AJC, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. J Hypertens 1997;15:1503-10.
197. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Inern Med 1996;156:278-85.
198. Chalmers JP, Morris MJ, Wing LMH, Cain MD, West MJ, Graham JR, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: A double blind factorial cross-over study. Aust NZ J Med 1986;16:475-80.
199. Chalmers JP, Korner PI, Tiller DJ, Bune AJ, Steiner JD, West MJ, et al. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. Med J Aust 1976;1:650-3.
200. Chalmers J, Horvath J, Tiller D, Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Lancet 1976;ii:328-31.
201. McCorvey E, Wright JT, Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clin Pharm 1993;12:300-5.
202. Myers MG, De Champlain J. Effect of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. Hypertension 1983;5:591-6.
203. Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol 1996;50:259-64.
204. Pool J, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens 1997;10:117-23.
205. Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: An option in first-line, antihypertensive treatment. Clin Ther 1993;15:779-87.
206. Moser M, Abraham PA, Bennett WM, Brachfeld N, Goodman RP, McKenney JM, et al. The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study. Clin Pharmacol Ther 1991;49:322-9.
207. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12:861-6.
208. Canter D, Frank GJ, Knapp LE, Phelps M, Quade M, Texter M. Quinapril and hydrochlorothiazide combination for control of hypertension: Assessment by factorial design. J Hum Hypertens 1994;8:155-62.
209. Fernández M, Madero R, González D, Camacho P, Villalpando J, Arriaga J. Combined versus single effect fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension 1994;23 (SUPPL I):I207-10.
210. Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994;8:283-8.
211. Pordy RC. Cilazapril plus hydrochlorothiazide: Improved efficacy without reduced safety in mild to moderate hypertension. Cardiology 1994;85:311-22.
212. Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992;6:133-8.
213. Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemyehu D, Simon JS, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35:182-8.
214. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, give alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 1996;5:17-24.
215. Goldberg MR, Rockhold FW, Offen WW, Dornseif BE. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther 1989;46:208-18.
216. Pool PE, Applegate WB, Woehler T, Sandall P, Cady WJ. A randomized, controlled trial comparing diltiazem, hydrochlorothiazide, and their combination in the therapy of essential hypertension. Pharmacotherapy 1993;13:487-93.
217. Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-9.
218. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12:797-805.
219. Jueng C, Halperin AK, Hasmimoto F, Callender K. Nifedipine GITS and hydrochlorothiazide in essential hypertension. J Clin Hypertens 1987;3:695-703.
220. Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 1982;128:903-7.
221. Jounela AJ, Lilja M, Lumme J, Mörlin C, Hoyem A, Wessel-aas T, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994;3:231-5.
222. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med 1994;154:737-43.
223. Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther 1978;24:192-8.
224. Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. β Blockade, diuretics, and salt restriction for the management of mild hypertension: A randomised double blind trial. BMJ 1984;289:406-9.
225. Salvetti A, Magagna A, Innocenti P, Ponzanelli F, Cagianelli A, Cipriani M, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: A crossover multicenter study. J Cardiovasc Pharmacol 1991;17:332-5.
226. Wing LMH, West MJ, Graham JR, Chalmers JP. Long-acting and short-acting diuretics in mild essential hypertension. Clin Exp Hypertens 1982;A4:1429-41.
227. Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol 1979;7:357-63.
228. Morledge JH, Ettinger B, Aranda J, McBarron F, Barra P, Gorwit J, et al. Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. J Am Geriatr Soc 1986;34:199-206.
229. Cranston WI, Juel-Jensen BE. The effects of spironolactone and chlorthalidone on arterial pressure. Lancet 1962;i:1161-4.
230. Ferrara LA, De Simone G, Mancini M, Fasano ML, Pasanisi F, Vallone G. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. Eur J Clin Pharmacol 1984;27:525-8.
231. Durel LA, Hayashi PJ, Weidler DJ, Schneiderman N. Effectiveness of antihypertensive medications in office and ambulatory settings: A placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. J Clin Pharmacol 1992;32:564-70.
232. Bradley K, Flack JM, Belcher J, Elmer P, Miller P, Grimm R. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. Am J Hypertens 1993;6:636-9.
233. Moser M. Low-dose diuretic therapy for hypertension. Clin Ther 1986;8:554-62.
234. McFate Smith WM, Feigal DW, Furberg CD, Greenlick M, Kuller L, Perry HM, et al. Use of diuretics in treatment of hypertension in the elderly. Drugs 1986;31:154-64.
235. Hall WD, Weber MA, Ferdinand K, Flamenbaum W, Marbury T, Jain AK, et al. Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. J Hum Hypertens 1994;8:571-5.
236. Schaller M, Waeber B, Brunner HR. Double-blind comparison of indapamide with a placebo in hypertensive patients treated by practicing physicians. Clin Exp Hypertens 1985;A7:985-94.
237. Fiddes R, Blumenthal J, Dawson JE, Dyckman E, Hammond PGS, Harris S, et al. Evaluation of indapamide 1.25mg once daily in elderly patients with mild to moderate hypertension. J Hum Hypertens 1997;11:239-44.
238. Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993;22 (Suppl 6):S78-S86.
239. Chalmers JP, Wing LMH, Grygiel JJ, West MJ, Graham JR, Bune AJ. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting. Eur J Clin Pharmacol 1982;22:191-6.
240. Taylor DR, Constable J, Sonnekus M, Milne FJ. Effect of indapamide on serum and red cell cations, with and without magnesium supplementation, in subjects with mild hypertension. S Afr Med J 1988;74:272-6.
241. Weidler D, Jallad NS, Curry C, Ferdinand K, Jain AK, Schnaper HW, et al. Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. J Clin Pharmacol 1995;35:45-51.
242. Ambrosioni E, Safar M, Degaute JP, Malin PL, MacMahon M, Pujol DR, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: Results of randomised double-blind controlled studies. J Hypertens 1998;16:1677-84.
243. Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension - A dose response study of perindopril and indapamide. J Hypertens 2000;18:317-25.
244. Carlsen JE, Køber L, Torp-Pedersen, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990;300:975-8.
245. Christiansen C, Christensen MS, Hagen C, Stocklund KE, Transbøl I. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. Acta Obstet Gynecol Scand 1981;60:407-12.
246. Horvath JS, Caterson RJ, Collett P, Duggin GG, Kelly DH, Tiller DJ. Labetalol and bendrofluazide: Comparison of their antihypertensive effects. Med J Aust 1979;1:626-8.
247. Webster J, Dollery CT, Hensby CN. Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension. Clin Sci 1980;59 (Suppl 6):125s-128s.
248. Wilcox RG. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. BMJ 1978;2:383-5.
249. Curry CL, Harris R, MacKay JH, Nugent CA, Ryan J, Schnaper H, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension. Clin Ther 1986;9:47-62.
250. Fernandez PG, Zachariah PK, Bryant DG, Missan SS. Antihypertensive efficacy of α-methyldopa, chlorothiazide and Supres-150 (α-methyldopa-chlorothiazide). Can Med Assoc J 1980;123:284-7.
251. McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: Comparison of low and conventional doses of cyclopenthiazide. BMJ 1988;297:95-8.
252. Chrysant SG, Chappel C, Farnham J, Levin B, Lueg M, McCluskey D, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992;32:61-5.
253. Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. J Hypertens 1991;9:1063-8.
254. Verdecchia P, Gatteschi C, Benemio G, Boldrini F, Guerrieri M, Porcellati C. Duration of the antihypertensive action of atenolol, enalapril and placebo. Int J Clin Pharmacol Ther Toxicol 1988;26:570-4.
255. Gostick NK, Mayhew SR, Million R, Sagar D, Suxena SR, Igram DF, et al. A dose-response study of atenolol in mild to moderate hypertension in general practice. Curr Med Res Opin 1977;5:179-84.
256. Cilliers AJ. Atenolol as primary therapy in previously untreated hypertensives and as an adjuvant to other therapy. S Afr Med J 1979;55:321-4.
257. Baez MA, Garg DC, Jallad NS, Weidler DJ. Antihypertensive effect of doxazosin in hypertensive patients: Comparison with atenolol. Br J Clin Pharmacol 1986;21 (Suppl 1):63S-67S.
258. Maclean D, Mitchell ET, Lewis R, Irvine N, McLay S, McEwen J, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1990;29:455-63.
259. Van Nueten L, Taylor FR, Robertson JIS. Nebivolol vs atenolol and placebo in essential hypertension: A double-blind randomised trial. J Hum Hypertens 1998;12:135-40.
260. Hansson L, Åberg H, Karlberg BE, Westerlund A. Controlled study of atenolol in treatment of hypertension. BMJ 1975;2:367-70.
261. Lange-Andersen KL, Ottmann W, Piatkowski W, Green KA. Working ability and exercise tolerance during treatment of mild hypertension. Int Arch Occup Environ Health 1985;56:49-55.
262. Tonkin AL, Wing LMH, Russell AE, West MJ, Bune AJC, Morris MJ, et al. Diltiazem and atenolol in essential hypertension: Additivity of effects on blood pressure and cardiac conduction with combination therapy. J Hypertens 1990;8:1015-18.
263. Streufert S, DePadova A, McGlynn T, Pogash R, Piasecki M. Impact of β-blockade on complex cognitive functioning. Am Heart J 1988;116:311-14.
264. Wing LMH, Chalmers JP, West MJ, Russell AE, Morris MJ, Cain MD. Enalapril and atenolol in essential hypertension: Attenuation of hypertensive effects in combination. Clin Exp Hypertens 1988;10:119-33.
265. Ekbom T., Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Wester P. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: A report from the STOP-Hypertension study. J Hypertens 1991;10:1525-9.
266. Saul P, Jones BP, Edwards KG, Tweed JA. Randomized comparison of atenolol and placebo in the treatment of anxiety: A double-blind study. Eur J Clin Pharmacol 1985;28:109-10.
267. Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. An assessment of lacidipine and atenolol in mild to moderate hypertension. Br J Clin Pharmacol 1994;37:45-51.
268. Tötterman K, Groop L, Groop P, Kala R, Tolppanen EM, Fyhrquist F. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. Eur J Clin Pharmacol 1984;26:13-7.
269. Jeffers TA, Webster J, Petrie JA. Atenolol once-daily in hypertension. Br J Clin Pharmacol 1977;4:523-7.
270. Clement DL, Bogaert MG, Pannier R. Effect of beta-adrenergic blockage on blood pressure variation in patients with moderate hypertension. Eur J Clin Pharmacol 1977;11:325-7.
271. Clement DL, De Pue NY, Packet L. Effect of calcium antagonists on ambulatory blood pressure and its variations. J Cardiovasc Pharmacol 1987;10(Suppl 10):S117-S119.
272. Petrie C, Jeffers TA, Robb OJ, Scott AK, Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. BMJ 1980;1:1573-4.
273. Houston MC, Burger C, Hays JT, Nadeau J, Swift L, Bradley CA, et al. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J 1990;120:172-9.
274. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;ii:650-3.
275. Wilcox RG, Hampton JR. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. Br Heart J 1981;46:498-502.
276. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: Placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100-4.
277. Broekman CPM, Haensel SM, Van de Ven LLM, Slob AK. Bisoprolol and hypertension: Effects on sexual functioning in men. J Sex Marital Ther 1992;18:325-31.
278. Van de Ven LLM, Mouthaan BJ, Hoes MJ. Treatment of hyperventilation syndrome with bisoprolol: A placebo-controlled clinical trial. J Psychosom Res 1995;39:1007-13.
279. Tseng C, Chiang F, Hsu K, Tseng Y, Hu W, Chen J, et al. Short-term efficacy and safety of bisoprolol in treatment of patients with mild-to-moderate hypertension - A two-center, double-blind study in Taiwan. Acta Cardiol Sin 1993;9:155-60.
280. Davidov ME, Singh SP, Vlachakis ND, Blumenthal JB, Simon JS, Bryzinski JS, et al. Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. Clin Cardiol 1994;17:263-8.
281. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991;68:61-4.
282. Williams RL, Goyle KK, Herman TS, Rofman BA, Ruoff GE, Hogan LB. Dose-dependent effects of betaxolol in hypertension: A double-blind multicenter study. J Clin Pharmacol 1992;32:360-7.
283. Ameling EH, De Korte DF, Man in 't Veld AJ. Impact of diagnosis and treatment of hypertension on quality of life: A double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991;18:752-60.
284. Salonen JT, Palminteri R. Comparison of two doses of betaxolol and placebo in hypertension: A randomised, double-blind cross-over trial. Eur J Clin Pharmacol 1982;23:491-4.
285. Gudbjornsdottir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Marin P, et al. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects. Eur J Clin Invest 1997;27:29-35.
286. Groop L, Tötterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. Acta Med Scand 1983;213:9-14.
287. Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994;235:335-41.
288. Jäättelä A, Baandrup S, Houtzagers J, Westergen G. The efficacy of low dose metoprolol CR/ZOK in mild hypertension and in elderly patients with mild to moderate hypertension. J Clin Pharmacol 1990;30 (Suppl):S66-S71.
289. Lepäntalo MJA, Tötterman KJ. Lower limb haemodynamics during antihypertensive treatment with metoprolol and propranolol. Int Angiol 1985;4:225-8.
290. MacMahon S, MacDonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985;i:1233-6.
291. Reybrouck T, Amery A, Fagard R, Jousten P, Lijnen P, Meulepas E. Beta-blockers: Once or three times a day? BMJ 1978;1:1386-8.
292. Vandongen R, Margetts B, Deklerk N, Beilin LJ, Rogers P. Plasma catecholamines following exercise in hypertensives treated with pindolol: Comparison with placebo and metoprolol. Br J Clin Pharmacol 1986;21:627-32.
293. Trafford JAP, Latta D, Little PS, Parsley J, Ankier SI. A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. Curr Med Res Opin 1989;11:550-6.
294. Kimura S, DeQuattro V, Hernandez PH, Lee DD. Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. Am J Cardiol 1988;62:751-4.
295. Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol 1980;9:209-12.
296. Vam Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-44.
297. Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and 1-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996;51:259-64.
298. Van Merode T, Van Bortel LM, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989;7 (Suppl 6):S262-S263.
299. Glassock RJ, Weitzman RE, Bennett CM, Maxwell M, Hamilton B, Winer N, et al. Pindolol: Effects on blood pressure and plasma renin activity. Am Heart J 1982;104:421-5.
300. Hamilton BP, Hamilton J, Kirkendall WM. Pulmonary function in hypertensive patients treated with pindolol: A report of two studies. Am Heart J 1982;104:432-7.
301. Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999;45:1170-7.
302. Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol 1998;18:441-6.
303. Pearson RM, Bulpitt CJ, Havard CWH. Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. Lancet 1979;i:697-9.
304. Dargie H, Cleland J, Findlay I, Murray G, McInnes G. Combination of verapamil and beta-blockers in systemic hypertension. Am J Cardiol 1986;57:80D-82D.
305. McInnes GT, Findlay IN, Murray G, Cleland JGF, Dargie HJ. Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens 1985;3 (Suppl 3):S219-S221.
306. Galloway DB, Glover SC, Hendry WG, Logie AW, Petrie JC, Smith MC, et al. Propranolol in hypertension: A dose-response study. BMJ 1976;2:140-2.
307. Hudson CFE. An evaluation of once daily long acting propranolol hydrochloride (Inderal LA and Half-Inderal LA) in the treatment of anxiety. A double-blind placebo-controlled general practice study. Br J Clin Pract 1988;42:419-26.
308. Moleur P, Peyrieux JC, Luciani J, David D, Boissel JP. Bopindolol in the treatment of moderate hypertension: A dose-response study. Fundam Clin Pharmacol 1988;2:431-40.
309. Adsett CA, Bellissimo A, Mitchell A, Wilczynski N, Haynes RB. Behavioral and physiological effects of a beta-blocker and relaxation therapy on mild hypertensives. Psychosom Med 1989;51:523-6.
310. Dupont AG, Vanderniepen P, Bossuyt AM, Jonckheer MH, Six RO. Nadolol in essential hypertension: Effect on ambulatory blood pressure, renal haemodynamics and cardiac function. Br J Clin Pharmacol 1985;20:93-9.
311. Casadei B, Conway J, Coats AJS, Bird R. Antihypertensive effect of carvedilol: A preliminary dose-response study. Clinical Invest 1992;70 (Suppl):S37-S38.
312. Dupont AG, Van der Niepen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt AM, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987;10 (Suppl 11):S130-S136.
313. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998;338:784-90.
314. Chrysant SG, Brown RD, Kem DC, Brown JL. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. Clin Pharmacol Ther 1983;33:741-6.
315. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1987;23:652-7.
316. Küppers HE, Jäger BA, Luszick JH, Gräve MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997;15:93-7.
317. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. Clin Pharmacol Ther 1991;50:96-106.
318. Forrette F, Handfield-Jones R, Henry-Amar M, Fouchard M, Bouchacourt P, Hervy M, et al. Rationale for ACE inhibition in the elderly: Treatment of arterial hypertension with enalapril. Gerontology 1987;33:9-16.
319. Van Baak MA, Mooij JMV, Wijnen JAG, Tan FS. Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension. Clin Pharmacol Ther 1991;50:221-7.
320. Bergstrand R, Herlitz H, Johansson S, Berglund G, Vedin A, Wilhelmsson C, et al. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol 1985;19:605-11.
321. Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton G, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 1989;62:112-17.
322. Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. Am J Hypertens 1989;2:352-4.
323. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997;79:431-5.
324. Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, Smith LK. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998;11:23-30.
325. Whelton A, Dunne B, Glazer N, Kostis JB, Miller WE, Rector DJ, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992;6:325-31.
326. Levine JH, Ferdinand KC, Cargo P, Laine H, Lefkowitz M. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995;8:494-9.
327. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-51.
328. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.
329. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6.
330. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.
331. Smith DHG, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-90.
332. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997;11 (Suppl 2):S61-S62.
333. Simon G, Morioka S, Snyder DK, Cohn JN. Increased renal plasma flow in long-term enalapril treatment of hypertension. Clin Pharmacol Ther 1983;34:459-65.
334. Sassano P, Chatellier G, Alhenc-Gelas F, Corvol P, Menard J. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. Am J Med 1984;77 (Suppl 2A):18-22.
335. Bilan A, Chibowska M, Palusinski R, Witczak, Ostrowski S, Makaruk B, et al. Enalapril (10 mg/day) in systemic sclerosis. Adv Exp Med Biol 1999;455:285-8.
336. Applegate WB, Cohen JD, Wolfson P, Davis A, Green S. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Am J Cardiol 1996;78:51-5.
337. Gerritsen TA, Bak AAA, Stolk RP, Jonker JJC, Grobbee DE. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. J Hypertens 1998;16:689-96.
338. Morgan TO, Morgan O, Anderson A. Effect of dose on through peak ratio of antihypertensive drugs in elderly hypertensive males. Clin Exp Pharmacol Physiol 1995;22:778-80.
339. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FIR. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: A 3-year placebo-controlled biopsy study. Metabolism 1998;47 (Suppl 1):12-15.
340. Luccioni R, Frances Y, Gass R, Gilgenkrantz JM. Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension. Clin Exp Hypertens 1989;A11:521-34.
341. West JNW, Smith SA, Stallard TJ, Littler WA. Effects of perindopril on ambulatory intra-arterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension. J Hypertens 1989;7:97-104.
342. Louis WJ, Workman BS, Conway EL, Worland P, Rowley K, Drummer O, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol 1992;20:505-11.
343. Chrysant SG, McDonald RH, Wright JT, Barden PL, Weiss RJ. Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. Clin Pharmacol Ther 1993;53:479-84.
344. Myers MG. A dose-response study of perindopril in hypertension: Effects on blood pressure 6 and 24 h after dosing. Am J Cardiol 1996;12:1191-6.
345. Overlack A, Adamczak M, Bachmann W, Bönner G, Bretzel RG, Derichs R, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. Am J Med 1994;97:126-34.
346. Cheung R, Lewanczuk RZ, Rodger NW, Huff MW, Oddou-Stock P, Botteri F, et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract 1999;53:584-92.
347. Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, Rosetti M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: A crossover study. J Hypertens 1987;5 (Suppl 4):S139-S142.
348. Schoenberger JA, Wilson DJ. Once-daily treatment of essential hypertension with captopril. J Clin Hypertens 1986;4:379-87.
349. Conway J, Way B, Boon N, Somers V. Is the antihypertensive effect of captopril influenced by the dosage frequency? A study with ambulatory monitoring. J Hum Hypertens 1988;2:123-6.
350. Lavessaro G, Ladetto PE, Valente M, Stramignoni D, Zanna C, Assogna G, et al. Ketanserin and captopril interaction in the treatment of essential hypertensives. Cardiovasc Drugs Ther 1990;4:119-22.
351. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984;144:1947-53.
352. Salvetti A, Circo A, Raciti S, Gulizia M, Cardillo R, Miceli S, et al. Captopril at 50 mg as well as at 100 mg once a day reduces blood pressure for up to 24 h: A double-blind randomized crossover study in mild to moderate hypertensives. J Hypertens 1988;6 (Suppl 4):S666-S668.
353. Wiggam MI, Hunter SJ, Atkinson AB, Ennis CN, Henry JS, Browne JN, et al. Captopril does not improve insulin action in essential hypertension: A double-blind placebo-controlled study. J Hypertens 1998;16:1651-7.
354. Drayer JIM, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983;5 (Suppl III): III108-III113.
355. Insua A, Ribstein J, Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgrad Med J 1988;64 (Suppl 3):59-62.
356. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension 1995;26:124-30.
357. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial. Lancet 1998;352:1978-81.
358. DeQuattro V, Lee D. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997;10 (Suppl):138S-145S.
359. Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. Am J Hypertens 1997;10:492-9.
360. De Bruijn JHB, Orofiamma BA, Pauly NC. Efficacy and tolerance of trandolapril (0.5-2 mg) administered for 4 weeks in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994;23 (Suppl 4):S60-S64.
361. Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998;11:322-7.
362. Pritchard G, Lyons D, Webster J, Petrie JC, MacDonald TM. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Br J Clin Pharmacol 1997;44:145-9.
363. Kohlmann O, Jardim PCBV, Oigman W. Brazilian multicenter on efficacy and tolerability in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. Arq Bras Cardiol 1999;72:553-7.
364. Mancia G, De Cesaris R, Fogari R, Lattuada S, Montemurro G, Palombo C, et al. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure. Am J Cardiol 1992;70:60D-66D.
365. Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension - A clinical trial of factorial design. Br J Clin Pharmacol 1998;45:491-5.
366. Mroczek WJ, Klein J, Burris JF. Dose-finding study of cilazapril (inhibace) in patients with uncomplicated essential hypertension. Clin Exp Hypertens 1991;A13:1415-32.
367. Prager G, Klein P, Schmitt M, Prager R. Antihypertensive efficacy of cilazapril 2.5 and 5.0 mg once-daily versus placebo on office blood pressure and 24-hour blood pressure profile. J Cardiovasc Pharmacol 1994;24 (Suppl 3):S93-S99.
368. Kobrin I, Güntzel P, Viskoper R, Paran E, Zimlichman R. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension. Drugs 1991;41:31-6.
369. Güntzel P, Kobrin I, Pasquier C, Zimlichman R, Viskoper JR. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients. J Cardiovasc Pharmacol 1991;17:8-12.
370. Lacourcière Y, Leenen F, Rangno R, Spence JD, Lenis JH, Myers MG. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy. Can J Cardiol 1994;10:605-10.
371. Fernandez PG, Bolli P, Lee C. The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen. Can J Cardiol 1990;6:53-8.
372. Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. J Cardiovasc Pharmacol 1992;20:451-7.
373. White WB, McCabe EJ, Hager WD, Schulman P. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise and ambulatory blood pressure. Clin Pharmacol Ther 1988;44 (Suppl 3):173-8.
374. Poirier L, Pyzyk M, Provencher P, Lacourcière Y. Comparative effects of 2.5 and 5 mg cilazapril versus placebo on daily blood pressure load. Am J Hypertens 1991;4:913-15.
375. Burris JF. The effect of ramipril on ambulatory blood pressure: A multicenter study. J Cardiovasc Pharmacol 1991;18 (Suppl 2):S131-S133.
376. McCarron D. 24-Hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects. Clin Cardiol 1991;14:737-42.
377. Schnaper HW. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1991;18 (Suppl 2):S128-S130.
378. Homuth V, Faulhaber H, Loose U, Löffler K, Luft FC. Usefulness of piretanide plus ramipril for systemic hypertension: A multicenter trial. Am J Cardiol 1993;72:666-71.
379. Villamil AS, Cairns V, Witte PU, Bertolasi CA. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo. Am J Cardiol 1987;59:110D-114D.
380. Kahan T, Eliasson K. The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension. Am J Hypertens 1999;12:1188-94.
381. Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. Clin Exp Hypertens 1999;21:1447-62.
382. Chan P, Lin C, Tomlinson B, Lin T, Lee Y. Additive effects of diltiazem and lisinopril in treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997;10:743-9.
383. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9.
384. Thürig C, Böhlen L, Schneider M, De Courten M, Shaw SG, Riesen W, et al. Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur J Clin Pharmacol 1995;49:21-6.
385. Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, et al. Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 1995;9:541-6.
386. Tomei R, Rossi L, Carbonieri E, Franceschini L, Molon G, Zardini P. Antihypertensive effect of lisinopril assessed by 24-hour ambulatory monitoring: A double-blind, placebo-controlled, cross-over study. J Cardiovasc Pharmacol 1992;19:911-14.
387. Polónia J, Martins L, Macedo F, Faria DB, Simões Brandão F, et al. Lisinopril and diltiazem reduce left ventricular mass without changing blood pressure in normotensive subjects with exaggerated blood pressure response to exercise. Rev Port Cardiol 1996;15:185-93.
388. Gomez JH, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 1989;28:415-20.
389. Cuspidi C, Lonati L, Sampieri L, Leonetti G, Muiesan ML, Agabiti-Rosei E, et al. Lack of effect of short-term lisinopril administration on left ventricular filling dynamics in hypertensive patients with diastolic dysfunction. Blood Pressure 1997;6:307-12.
390. Lee AFC, Dick JBC, Bonnar CE, Struthers AD. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci 1999;96:441-8.
391. Maclean D. Quinapril: A double-blind, placebo-controlled trial in essential hypertension. Angiology 1989;40:370-81.
392. Säynävälammi P, Pörsti I, Pörsti P, Nurmi A, Seppälä E, Manninen V, et al. Effects of the converting enzyme inhibitor quinapril on blood pressure, renin-angiotensin system and prostanoids in essential hypertension. J Cardiovasc Pharmacol 1988;12:88-93.
393. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Sweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991;17:13-19.
394. Kjeldsen SE, Gupta RK, Krause L, Weder AB, Julius S. Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril. Am Heart J 1992;123:1433-8.
395. Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-61.
396. Ford NF, Fulmor IE, Nichola PS, Alpin PG, Herron JM. Fosinopril monotherapy: Relationship between blood pressure reduction and time of administration. Clin Cardiol 1993;16:324-30.
397. Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991;17:636-42.
398. Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: Findings of the Fosinopril Study Group II. Clin Ther 1990;12:520-33.
399. Guitard C, Lohmann FW, Alfiero R, Ruina M, Alvisi V. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. Cardiovasc Drugs Ther 1997;11:449-57.
400. Guitard C, Sassano P, Tzincoca C, Duchiez J, Safar ME. Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension. Blood Press 1994;3 (Suppl 2):61-8.
401. Guitard C, Alvisi V, Maibach E, Franck J, Cocco G, Boxho G, et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. Blood Press 1994;3 (Suppl 2):81-7.
402. Fairhurst GJ. A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. Blood Press 1994;3 (Suppl 2):77-80.
403. Frishman WH, Ram CVS, McMahon FG, Chrysant SG, Graff A, Kupiec JW, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol 1995;35:1060-6.
404. Kuschnir E, Acuña E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al. Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 10 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213-24.
405. Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. J Human Hypertens 1999;13:337-42.
406. Fridman K, Wysocki M, Friberg P, Anderson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hum Hypertens 2000;13:1045-8.
407. Christensen PK, Lund S, Parving H-H. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 2001;60:1435-42.
408. Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11:S55-S56.
409. Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - A population analysis. Eur J Clin Pharmacol 1997;53:221-8.
410. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin-II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997;11:S49-S53.
411. Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001;21:17-23.
412. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999;12:1181-7.
413. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin-II antagonist, in comparison with losartan. Blood Press 1998;7:53-9.
414. Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998;82:961-5.
415. Bell TP, DeQuattro V, Lasseter KC, Ruff D, Hardison JD, Cushing D, et al. Effective dose range of candesartan cilexetil for systemic hypertension. Am J Cardiol 1999;83:272-5.
416. Zuschke CA, Keys I, Munger MA, Carr AA, Marinides GN, Flanagan TL, et al. Candesartan cilexetil: Comparison of once-daily versus twice-daily administration for systemic hypertension. Clin Ther 1999;21:464-74.
417. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, et al. A comparison of angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414-17.
418. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810.
419. Neutel J, Weber M, Pool J, Smigh D, Fitzsimmons S, Chiang Y-T, et al. Valsartan, a new angiotensin-II antagonist: Antihypertensive effects over 24 hours. Clin Ther 1997;19:447-58.
420. Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-15.
421. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin-II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53.
422. Mallion M, Siche JP, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin-II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-64.
423. Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualsiero P, Varricchio G, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997;11:307-12.
424. Fagard R, Lijnen P, Pardaens K, Thijs L, Vinck W. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. J Hum Hypertens 2001;15:161-7.
425. Cheetham C, O'Driscol G, Standon K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci 2001;100:13-17.
426. Pancera P, Persciuttini B, Sansone S, Montagna L, Paluani F, Covi G, et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. J Hypertens 1999;17:513-21.
427. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995;13:S29-S33.
428. Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 1997;6:35-43.
429. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin-II antagonist. J Hypertens 2001;19:S41-S48.
430. Pool JL, Glazer R, Chiang Y-T, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin-II receptor blocker. J Hum Hypertens 1999;13:275-81.
431. Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and tolerability of irbesartan, an angiotensin-II receptor antagonist, in primary hypertension. Clin Drug Invest 1998;3:217-27.
432. Fogari R, Ambrosoli S, Corradi L, Esposti ED, Mos L, Nami R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hum Hypertens 1997;15:1511-18.
433. Pool JL, Guthrie RM, Littlejohn TW, Raskin P, Shephard AMM, Weber A, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70.
434. Benetos A, Gautier S, Laflèche A, Topouchian J, Frangin G, Girerd X, et al. Blockade of angiotensin II type 1 receptors: Effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res 2000;37:8-15.
435. McGill JB, Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomised double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833-50.
436. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998;15:206-17.
437. Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M. Efficacy and tolerability of tasosartan, a novel angiotensin-II receptor blocker: Results from a 10-week, double-blind, placebo controlled, dose-titration study. Am Heart J 1999;137:118-25.
438. Feldman R, Chattman MS, Lonigro A, Sievers RJ. Tasosartan in patients with essential hypertension: A randomized, double-blind, dose-titration study. Adv Ther 1997;14:290-303.
439. Rhéaume C, Waib PH, Lacourcière Y, Cléroux J. Effects of angiotensing antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. J Hypertens 1998;16:2085-9.
440. Lacourcière Y, Pool JL, Svetkey L, Gradman AH, Larochelle P, De Champlain J, et al. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Am J Hypertens 1998;11:454-61.
441. Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin-II antagonist, in patients with systemic hypertension. Clin Ther 1999;21:442-53.
442. Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens 1999;17:129-36.
443. White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens 2001;14:1248-55.
444. Schmitz A, Pedersen MM, Mogensen CE. Effects of felodipine on urinary albumin excretion and metabolic control in hypertensive non-insulin-dependent diabetics. Am J Hypertens 1990;3:611-17.
445. Campbell LM, Cowen KJ, Cranfield FR, Goves JR, Jones DF, Lees CTW, et al. Felodipine-ER once daily as monotherapy in hypertension. J Cardiovasc Pharmacol 1990;15:569-73
446. Cooperative Study Group. Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Drugs 1987;34(Suppl 3):139-48.
447. Crozier IG, Ikram H, Nicholls MG, Low CJS. Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension. Cardiovasc Drugs Ther 1990;4:439-42.
448. Fagan TC. Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. J Am Geriatr Soc 1997;45:712-717.
449. Hamilton DV, Barnes PC, Bowles RML, Rajaratnam DV, Comerford MB, Ginks WR, et al. Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension. J Cardiovasc Pharmacol 1987;10 (Suppl S): S111-S113.
450. Hosie J, Mulder AW, Westberg B. Felodipine once daily in elderly hypertensives. J Hum Hypertens 1991;5:49-53.
451. Liedholm H, Melander A. A placebo-controlled dose-response study of felodipine extended release in hypertensive patients. J Cardiovasc Pharmacol 1989;14:109-13.
452. Madsen JK, Zachariae H, Pedersen EB. Effects of the calcium antagonist felodipine on renal aerodynamics, tubular sodium handling, and blood pressure in cyclosporin-treated dermatological patients. Nephrol Dial Transplant 1997;12:480-4.
453. McGrath BP, Watts RW, Elmfeldt DB. Clinical equivalence of two tablet formulations of felodipine. Eur J Clin Pharmacol 1995;49:169-72.
454. Pannarale G, Puddu PE, Monti F, Irace L, Bentivoglio M, Collauto F, et al. Twenty-four antihypertensive efficacy of felodipine 10 mg extended-release: The Italian inter-university study. J Cardiovasc Pharmacol 1996;27:255-61.
455. Porcellati C, Verdecchia P, Gatteschi C, Benemio G, Guerrieri M, Boldrini F, et al. Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. Eur J Clin Pharmacol 1989;37:555-7.
456. Bonaduce D, Canonico V, Petretta M, Forgione L, Ianniciello A, Cavallaro V, et al. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: A randomized, double-blind, cross-over study. Eur J Clin Pharmacol 1997;53:95-100.
457. Van Ree JW, Van Der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: Effect on ambulatory blood pressure and quality of life. J Hum Hypertens 1996;10:613-18.
458. Weber MA, Goldberg AI, Faisons EP, Lipschutz K, Shapiro DA, Nelson EB, et al. Extended-release felodipine in patients with mild to moderate hypertension. Clin Pharmacol Ther 1994;55:346-52.
459. Wester A, Lorimer AR, Westberg B. Felodipine extended release in mild to moderate hypertension. Curr Med Res Opin 1991;12:275-81.
460. Bossini A, Di Veroli C, Cavallotti G, Cagli V. Felodipine ER formulation in the treatment of mild hypertension: Efficacy and tolerability vs placebo. Br J Clin Pharmacol 1990;30:567-71.
461. Andersson OK, Persson B, Hedner T, Aurell M, Wysocki M. Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: A controlled study in middle-aged hypertensive men. J Hypertens 1989;7:465-9.
462. Arosio E, Pancera P, Priante F, Ribul M, De Marchi S, Lechi A. Effects of sustained-release isradipine on blood pressure and peripheral hemodynamics in hypertensive patients. Clin Ther 1993;15:705-13.
463. Arzilli E, Gandolfi E, Del Prato C, Innocenti P, Ponzanelli F, Gaiazza A, et al. Antihypertensive effect of once daily sustained release isradipine: A placebo controlled cross-over study. Eur J Clin Pharmacol 1993;44:23-5.
464. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. J Clin Pharmacol 1995;35:239-43.
465. Cléroux J, Yardley C, Marshall A, Coulombe D, Lacourcière Y. Antihypertensive and hemodynamic effects of calcium channel blockade with isradipine after acute exercise. Am J Hypertens 1992;5:84-7.
466. Fogari R, Malacco E, Tettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension: A double-blind study with 24 h ambulatory monitoring. Br J Clin Pharmacol 1993;35:51-4.
467. Holmes DG, Isradipine: A slow-release formulation given once daily controls blood pressure for 24h. Am J Hypertens 1993;6:74S-76S.
468. The Italian-Belgian Isradipine Study Group. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. Am J Med 1989;86:94-7.
469. Kirch W, Burger KJ, Weidinger G, Welzel D. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. J Cardiovasc Pharmacol 1990;15 (Suppl 1):S55-S59.
470. Low CJS, Foy SG, Chaudhary H, Crozier IG, Baskaranathan S, Ikram H. Twenty-four hour profile of the anti-hypertensive action of isradipine in essential hypertension. Blood Press 1993;2:59-61.
471. Nelson EB, Pool JL, Taylor AA. Antihypertensive activity of isradipine in humans: A new dihydropyridine calcium channel antagonist. Clin Pharmacol Ther 1986;40:694-7.
472. O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H. Effect of isradipine on in-vivo platelet function. Thromb Res 1997;86:363-71.
473. Rab SM, Mirza MA, Khan MH, Samad A, Ahmed M. Double-blind multicentre isradipine dose-confirmation study in Pakistan. Drugs 1990;40 (Suppl 2):30-2.
474. Simonsen K. Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. Am J Med 1989;86:91-3.
475. Staessen J, Lijnen P, Fagard R, Hespel P, Tan WP, Devos P, et al. Effects of the new calcium entry blocker isradipine (NP 200-110) in essential hypertension. J Cardiovasc Pharmacol 1989;13:271-6.
476. Bremmer AD, Fell PJ, Hosie J, James IGV, Saul PA, Taylor SH. Early side-effects of antihypertensive therapy: Comparison of amlodipine and nifedipine retard. J Hum Hypertens 1993;7:79-81.
477. Carr AA, Bottini PB, Prisant LM, Mulligan S, Devane JG, Fisher L, et al. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992;69 (SupplE):28E-32E.
478. Corbin DOC, Wood DA, Macintyre CGA, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J 1986;7:165-70
479. Eggertsen R, Hansson L. Effects of treatment with nifedipine and metoprolol in essential hypertension. Eur J Clin Pharmacol 1982;21:389-90.
480. Feig PU, Gibson L, MacCarthy EP, Pettis PP, Schwartz L. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Clin Ther 1993;15:963-75.
481. Handa K, Mori T, Tanaka H, Takada Y, Matsunagga A, Kiyonaga A, et al. Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects. Cardiovasc Drugs Ther 1992;6:85-90.
482. Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. Drugs 1994;48:23-31.
483. Landmark K, Dale J. Antihypertensive, haemodynamic and metabolic effects of nifedipine slow-release tablets in elderly patients. Acta Med Scand 1985;218:389-96.
484. Ozenne G, Moore ND, Leprovost A, Tardif C, Boismare F, Pasquis P, et al. Nifedipine in chronic bronchial asthma: A randomised double-blind crossover trial against placebo. Eur J Resp Dis 198:67:238-43.
485. Patakas D, Maniki E, Tsãra V, Dascalõpõulou E. Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol 1987;79:959-63.
486. Salvetti A, Virdis A, Taddei S, Ambrosoli S, Caiazza A, Gandolfi E, et al. Trough:peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: An Italian multicentre study. J Hypertens 1996;14:661-7.
487. Sand J, Nordback I, Koskinen M, Matikainen M, Lindholm TS. Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol 1993;4:530-5.
488. De Simone G, Ferrara LA, Fasano ML, Di Lorenzo L, Lauria R. Slow-release nifedipine versus placebo in the treatment of arterial hypertension. Jpn Heart J 1985;26:219-25.
489. Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension. Can J Cardiol 1997;13:921-7.
490. Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained release formulation of nifedipine. J Clin Pharmacol 1990;30:1012-19.
491. Harder S, Rietbrock S, Thürmann P. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. Drug Res 1994;44:133-6.
492. Licata G, Scaglione R, Ganguzza A, Parrinello G, Costa R, Merlino G, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. Eur J Clin Pharmacol 1993;45:307-11.
493. Lorimer AR, Smedsrud T, Walker P, Tyler HM. A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. J Hum Hypertens 1989;3:191-6.
494. Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. Am J Cardiol 1990;66:1269-71.
495. Mehta JL, Lopez LM, Vlachakis ND, Gradman AH, Nash DT, O'Connell MT, et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J 1993;125:1704-9.
496. Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988;12 (Suppl 7):S79-S84.
497. Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC, Towler HM. Once daily amlodipine in the treatment of mild to moderate hypertension. Br J Clin Pharmacol 1987;24:713-19.
498. Frick MH, McGibney D, Tyler HM. Amlodipine: A double-blind evaluation of the dose-response relationship in mild to moderate hypertension. J Cardiovasc Pharmacol 1988;12 (Suppl 7):S76-S78.
499. Ahmed JH, Elliott HL, Hosie J, Rafish E, Reid JL. Effects of nicardipine on the metabolic responses to food and exercise. J Hum Hypertens 1992;6:139-44.
500. Bellett M, Pagny J-Y, Chatellier G, Corvol P, Ménard J. Evaluation of slow release nicardipine in essential hypertension by casual and ambulatory blood pressure measurements. Effects of acute versus chronic administration. J Hypertens 1987;5:599-604.
501. Cox JP, Ryan J, O'Brien E, O'Malley K. The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension. Br J Clin Pharmacol 1989;28:79-82.
502. Fagan TC, Tyler ED, Reitman MA, Kenley S, Weber MA. Sustained-release nicardipine in mild-to-moderate hypertension. Chest 1993;104:427-33.
503. Mazzola C, Borgnino C, Colombo D, Lissoni F, Serra G, Turri DR, et al. Antihypertensive and hemodynamic effects of slow-release nicardipine. Int J Clin Pharmacol Ther Toxicol 1988;26:503-8.
504. Salvetti A, Cardellino G, Pesenti M, Caiazza A, Ghisoni F, Del Prato C, et al. Antihypertensive effect of slow-release nicardipine. A placebo-controlled cross-over study. Eur J Clin Pharmacol 1989;36:439-42.
505. Soro S, Cocca A, Pasanisi F, Tommaselli A, De Simone G, Costantino G, et al. The effects of nicardipine on sodium and calcium metabolism in hypertensive patients: A chronic study. J Clin Pharmacol 1990;30:133-7.
506. Webster J, Petrie JC, Jeffers TA, Roy-Chaudhury P, Crichton W, Witte K, et al. Nicardipine sustained release in hypertension. Br J Clin Pharmacol 1991;32:433-9.
507. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831-8.
508. Opie LH, Müller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YY, et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. Am J Hypertens 1997;10:250-60.
509. Lijnen P, Petrov V. Blood pressure and cationic transport systems during combined calcium channel blocker and calcium administration in males. Methods Find Exp Clin Pharmacol 1996;18:287-94.
510. Morris AD, Donnelly R, Connelly JMC, Reid JL. Effects of the calcium antagonist lacidipine on insulin sensitivity in essential hypertension. Horm Metab Res 1994;26:257-9.
511. Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. J Cardiovasc Pharmacol 1991;17:(Suppl 4):S39-S44.
512. Ueda S, Donnelly R, Panfilov V, Morris AD, Elliott HL. Lacidipine: Effects on vascular pressure responses throughout the dosage interval in normotensive subjects. Br J Clin Pharmacol 1998;46:127-32.
513. Lacourcière Y, Poirier L, Lefebvre J, Burford RG. Clinical efficacy of force titrated doses of diltiazem extended-release. Am J Hypertens 1995;8:282-6.
514. Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, et al. A dose-response trial of once-daily diltiazem. Am Heart J 1992;123:1022-6.
515. Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCL, in mature and elderly hypertensive patients. Clin Ther 1994;16:209-21.
516. Dupont AG, Coupez JM, Jensen P, Coupez-Lopinot R, Schoors DF, Hermanns P, et al. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension. Cardiovasc Drugs Ther 1991;5:701-8.
517. Meeves SG, Park GD. The use of confidence intervals to describe the precision of trough/peak ratios for diltiazem CD in the treatment of hypertension. J Clin Pharmacol 1994;34:231-5.
518. Meeves S, Hafner K, Park G, Weber M. Three-period crossover trial with ambulatory blood pressure monitoring for evaluating antihypertensive therapy. Am Heart J 1995;130:841-8.
519. Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: Randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985;56 (suppl H):86H-91H.
520. Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: Double-blind, placebo controlled study with 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992;32:808-15.
521. Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992;14:148-57.
522. Van Merode T, Van Bortel L, Smeets FAM, Böhm R, Mooij J, Rahn KH, et al. The effects of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. J Cardiovasc Pharmacol 1990;15:109-13.
523. Hedbäck B, Hermann LS. Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension. Acta Med Scandi 1984;681 (Suppl):129-35.
524. Kimose H-H, Bagger JP, Aagaard MT, Paulsen PK. Placebo-controlled, double-blind study of the effect of verapamil in intermittent claudication. Angiology 1990;41:595-8.
525. Carr AA, Bottini PB, Prisant LM, Fisher LD, Devane JG, O'Brien DE, et al. Once-daily verapamil in the treatment of mild-to-moderate hypertension: A double-blind placebo-controlled dose-ranging study. J Clin Pharmacol 1991;31:144-50.
526. McMahon FG, Reder RF. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. J Clin Pharmacol 1989;29:1003-7.
527. Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J 1996;132:1202-6.
528. Corea L, Bentivoglio M, Berioli S, Bianchini C, Savino K, Sardina M. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind placebo-controlled study with 24-hour ambulatory blood pressure monitoring. Cardiovasc Drugs Ther 1990;4:1501-8.
529. Lewis GRJ, Morley KD, Lewis BM, Bones PJ. The treatment of hypertension with verapamil. NZ Med J 1978;87:351-4.
530. Van Bortel LMAB, Schiffers PMH, Böhm ROB, Mooij JMV, Rahn KH, Struyker Boudier HAJ. The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients. Eur J Clin Pharmacol 1990;39 (Suppl 1):S39-S40.
531. White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995;76:375-80.